Antitumor activity of nivolumab on hemodialysis after renal allograft rejection

BACKGROUND: Nivolumab (Opdivo™) is a novel IgG4 subclass programmed death-1 (PD-1) inhibiting antibody that has demonstrated breakthrough-designation anti-tumor activity. To date, clinical trials of nivolumab and other checkpoint inhibitors have generally excluded patients with solid organ transplan...

Descripción completa

Detalles Bibliográficos
Autores principales: Ong, Michael, Ibrahim, Andrea Marie, Bourassa-Blanchette, Samuel, Canil, Christina, Fairhead, Todd, Knoll, Greg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067882/
https://www.ncbi.nlm.nih.gov/pubmed/27777773
http://dx.doi.org/10.1186/s40425-016-0171-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067882/
https://www.ncbi.nlm.nih.gov/pubmed/27777773
http://dx.doi.org/10.1186/s40425-016-0171-8

Ejemplares similares